Kepos Capital LP purchased a new stake in shares of Natera Inc (NASDAQ:NTRA) in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor purchased 34,381 shares of the medical research company’s stock, valued at approximately $823,000.
Other hedge funds and other institutional investors also recently modified their holdings of the company. Tygh Capital Management Inc. raised its holdings in Natera by 32.3% in the 2nd quarter. Tygh Capital Management Inc. now owns 300,036 shares of the medical research company’s stock worth $5,647,000 after purchasing an additional 73,301 shares in the last quarter. Prescott Group Capital Management L.L.C. bought a new position in Natera in the 2nd quarter worth $572,000. EAM Investors LLC bought a new position in Natera in the 2nd quarter worth $3,868,000. Gilder Gagnon Howe & Co. LLC bought a new position in Natera in the 3rd quarter worth $1,035,000. Finally, Sei Investments Co. bought a new position in Natera in the 2nd quarter worth $928,000. Institutional investors and hedge funds own 87.90% of the company’s stock.
Shares of NASDAQ NTRA opened at $18.48 on Tuesday. The company has a debt-to-equity ratio of 1.30, a current ratio of 2.44 and a quick ratio of 2.32. Natera Inc has a 12 month low of $8.60 and a 12 month high of $29.62. The firm has a market capitalization of $1.07 billion, a price-to-earnings ratio of -7.70 and a beta of 2.05.
Several research analysts have commented on NTRA shares. Morgan Stanley upped their price objective on shares of Natera from $21.00 to $41.00 and gave the stock an “overweight” rating in a report on Friday, September 28th. JPMorgan Chase & Co. started coverage on shares of Natera in a report on Friday, October 5th. They issued a “neutral” rating and a $26.00 price objective for the company. Canaccord Genuity upped their price objective on shares of Natera from $25.00 to $29.00 and gave the stock a “buy” rating in a report on Thursday, August 16th. TheStreet upgraded shares of Natera from a “d” rating to a “c-” rating in a report on Thursday, August 9th. Finally, Cowen restated a “buy” rating and issued a $30.00 price objective on shares of Natera in a report on Friday, November 9th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. The stock presently has an average rating of “Buy” and an average price target of $28.25.
In related news, COO Steven Leonard Chapman sold 45,000 shares of the stock in a transaction dated Tuesday, September 11th. The shares were sold at an average price of $25.16, for a total value of $1,132,200.00. Following the completion of the transaction, the chief operating officer now directly owns 16,628 shares in the company, valued at approximately $418,360.48. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Jonathan Sheena sold 166,667 shares of the stock in a transaction dated Friday, September 14th. The stock was sold at an average price of $24.27, for a total transaction of $4,045,008.09. Following the completion of the transaction, the insider now owns 481,975 shares of the company’s stock, valued at $11,697,533.25. The disclosure for this sale can be found here. Over the last quarter, insiders sold 2,014,988 shares of company stock valued at $48,674,710. 13.18% of the stock is owned by company insiders.
ILLEGAL ACTIVITY WARNING: This report was first reported by Community Financial News and is the sole property of of Community Financial News. If you are reading this report on another website, it was illegally copied and reposted in violation of US & international trademark and copyright laws. The original version of this report can be accessed at https://www.com-unik.info/2018/12/04/34381-shares-in-natera-inc-ntra-acquired-by-kepos-capital-lp.html.
Natera, Inc, a diagnostics company, provides preconception and prenatal genetic testing services. It primarily offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases that could be passed on to the carrier's children; and Spectrum pre-implantation genetic screening and Spectrum pre-implantation genetic diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle.
Further Reading: Using the New Google Finance Tool
Want to see what other hedge funds are holding NTRA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Natera Inc (NASDAQ:NTRA).
Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.